Morgan Stanley upgraded Sanofi (SNY) to Overweight from Equal Weight with a price target of $58, up from $56. The firm believes the recent pullback in the shares brings an attractive entry point. The clarity on amlitelimab removes an overhang on the stock, and the equity story can shift from research and development execution back to Sanofi’s earnings momentum in the near-term, the analyst tells investors in a research note. Morgan Stanley believes margin expansion in 2026 now looks possible for the company, supported by continued sales momentum.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Sanofi Stock (SNY) Revives after Trial Miss as Analyst Hails ‘Buying Opportunity’
- Sanofi’s ‘disappointing’ atopic dermatitis data sends Nektar higher
- Sanofi’s Amlitelimab Shows Promising Results in Atopic Dermatitis Study
- Piper says competitor AD data reinforces Nektar’s REZPEG differentiated profile